预约演示
更新于：2025-02-06
Rupatadine Fumarate
富马酸卢帕他定
更新于：2025-02-06
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30ClN3O4 |
InChIKeyJYBLCDXVHQWMSU-WLHGVMLRSA-N |
CAS号182349-12-8 |
关联
66
项与 富马酸卢帕他定 相关的临床试验CTRI/2024/11/076733
A comparative study on safety and efficacy of oral fexofenadine and oral rupatadine among patients with allergic rhinitis - NIL
NCT06709092
Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
CTR20232038
富马酸卢帕他定片在健康成年受试者中进行的单中心、随机、开放、单次给药、两序列、四周期、完全重复交叉、空腹和餐后生物等效性试验
100 项与 富马酸卢帕他定 相关的临床结果
登录后查看更多信息
100 项与 富马酸卢帕他定 相关的转化医学
登录后查看更多信息
100 项与 富马酸卢帕他定 相关的专利（医药）
登录后查看更多信息
337
项与 富马酸卢帕他定 相关的文献（医药）2025-01-01Asian Pacific journal of allergy and immunology4区 · 医学
Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans
4区 · 医学
Article
作者: Kim, Hyung Gu ; Kim, Hyo Yeol ; Kim, Dae Woo ; Kim, Chang-Hoon ; Rhee, Chae-Seo ; Kim, Jin Kook ; Kim, Sung Wan ; Kim, Jeong-Whun ; Won, Tae-Bin ; Kim, Soo Whan ; Kim, Young Hyo
BACKGROUND:
The efficacy of rupatadine for the treatment of AR has been confirmed in numerous clinical studies, however there are very few studies on asian patients.
OBJECTIVE:
To assess the safety and efficacy of rupatadine fumarate in the treatment of Korean perennial allergic rhinitis (PAR) patients.
METHODS:
A multicenter, double-blind, randomized, placebo-controlled, comparative study of rupatadine fumarate and bepotastine besilate was conducted. Each group was administered rupatadine, bepotastine or placebo for 4 weeks. Primary parameters for efficacy included morning and evening symptom reduction from baseline at 4 weeks. Treatment safety and tolerability were evaluated according to a self-reported incidence and type of adverse events at each follow up visit.
RESULTS:
Rupatadine showed a significant reduction in symptoms at morning and evening evaluations, in both 5TSS (-5.69, P < 0.0006) and 4NTSS (-4.74, P < 0.0015) compared to placebo. There was a significant reduction from baseline for 5TSS (-65.4%, P = 0.002) and 4NTSS (-63.7%, P = 0.003) with rupatadine compared with placebo. At evening evaluations, there were significant reductions of 5TSS (-63.2%, P = 0.009) and 4NTSS (-61.6%, P = 0.013) for the rupatadine group. Compared with bepotastine, rupatadine showed greater reduction in the morning symptoms at 4 weeks. When individual symptoms were assessed with 12-hour reflective mean daily symptom score, rupatadine showed better efficacy than placebo in sneezing (P = 0.016) and rhinorrhea (P = 0.097). The rate of adverse events showed no statistical significance.
CONCLUSIONS:
Rupatadine is a safe and effective treatment option for Korean PAR patients and possibly a better choice over bepotastine for controlling morning symptom.
2025-01-01JOURNAL OF VETERINARY MEDICAL SCIENCE
Comparing the effectiveness of four antihistamines with olopatadine in healthy Thoroughbred horses
Article
作者: MITA, Hiroshi ; IKEDA, Yasuhiko ; TAMURA, Norihisa ; OHTA, Minoru ; KURODA, Taisuke
We compared the antihistamine effect of four new antihistamines with olopatadine, which is used to treat equine allergic diseases. Six healthy Thoroughbred horses received oral doses of olopatadine (50 mg), levocetirizine (50 mg), bilastine (200 mg), rupatadine (100 mg), and desloratadine (50 mg) at >2-week intervals. The effects were investigated by measurement of the wheal area induced by histamine intradermal injection, and inhibition rate was compared with positive and negative controls. The maximum wheal inhibition rate (mean ± SD) of olopatadine (85.3% ± 7.7%) was significantly higher than those of bilastine (51.1% ± 11.8%), rupatadine (55.3% ± 6.6%), and desloratadine (59.8% ± 6.4%), but not levocetirizine (85.4% ± 8.0%). Levocetirizine is expected to have a high antihistamine effect on horses.
2024-11-01TOXICOLOGY AND APPLIED PHARMACOLOGY
Protective effect of rupatadine on testicular ischemia/reperfusion injury in rats: Modulation of IL-6/STAT3, Akt/ mTOR signaling pathways
Article
作者: Ahmed, Sara M ; Abdel-Aziz, Asmaa Mohamed ; Thabit, Dina Moustafa ; Ahmed, Sara M. ; Abdelmonaem, Alyaa Abdelfattah ; Marey, Heba
BACKGROUNDS & AIM:
Spermatic cord rotation is a common problem in the field of urology, that finally results in necrosis of testicular tissue as well as male infertility. Rupatadine (RUP); a second-generation antihistaminic drug; demonstrated to have a possible protective effect in variable ischemia/reperfusion (I/R) rat models, but its role has not been studied yet in testicular I/R model.
MATERIAL & METHODS:
The present study investigated RUP ability to ameliorate testicular I/R injury. The study includes four groups (6 rats/group); sham group, sham group pretreated with RUP (6 mg/kg/day; orally) for 14 days, I/R group, and RUP-I/R pretreated group.
KEY FINDINGS:
The results demonstrated that I/R significantly lowered serum testosterone level and testicular tissue content of reduced glutathione. Besides, a significant elevation in malondialdehyde level, hypoxia-inducible factor-1, signal transducers and activators of transcription-3 (STAT-3), interleukin-6 (IL-6), histamine, and platelet activating factor levels along with an inhibition in testicular tissue level of vascular endothelial growth factor-A (VEGF-A) with an evident increase in caspase-3 immunoexpression in germ cells. Also, I/R significantly lowered p-AKT and mTOR testicular expression. While, RUP-I/R pretreated group showed a reversal in the testicular I/R damaging effects in a significant manner in the all the aforementioned parameters.
CONCLUSION:
Based on these findings; RUP was proved to have a possible protective effect in testicular I/R injury via its antioxidant effect and its ability to modulate IL-6/STAT3, Akt/ mTOR inflammatory signaling pathways with improvement in the testicular VEGF-A level.
100 项与 富马酸卢帕他定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2017-09-27 | |
| 皮炎 | 日本 | 2017-09-27 | |
| 湿疹 | 日本 | 2017-09-27 | |
| 湿疹 | 日本 | 2017-09-27 | |
| 湿疹 | 日本 | 2017-09-27 | |
| 瘙痒 | 日本 | 2017-09-27 | |
| 慢性荨麻疹 | 加拿大 | 2017-01-16 | |
| 常年性变应性鼻炎 | 加拿大 | 2017-01-16 | |
| 季节性过敏性鼻炎 | 加拿大 | 2016-07-20 | |
| 过敏性鼻炎 | 西班牙 | 2001-10-30 | |
| 荨麻疹 | 西班牙 | 2001-10-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 範願膚蓋選夢齋網衊膚(製鹽夢選製積鑰顧淵衊) = Rupatadine is the likely cause of sleep terrors due to temporal association. Discontinuation of Rupatadine and initiation of Bilastine (20 mg daily) led to immediate and profound improvement in sleep quality, cessation of sleep terrors, and continued anaphylaxis remission. Night terrors are a rare Rupatadine side effect with significant impact on quality of life. 鑰鑰夢願齋願糧淵選夢 (繭鹹觸窪蓋艱鏇網夢糧 ) | 积极 | 2024-10-24 | |||
N/A | - | - | Standard Premedications | 衊齋築夢願繭壓廠獵願(鹹選齋願築糧遞構艱醖) = 選膚鏇顧壓鬱顧網鹽製 鬱製簾願壓衊顧構獵衊 (獵鹹醖遞艱鏇艱簾範範, 0 ~ 63) 更多 | - | 2019-06-12 | |
衊齋築夢願繭壓廠獵願(鹹選齋願築糧遞構艱醖) = 鏇鬱憲鏇鹹齋觸獵憲鑰 鬱製簾願壓衊顧構獵衊 (獵鹹醖遞艱鏇艱簾範範, 0 ~ 50) 更多 | |||||||
临床2期 | 248 | 鏇餘憲遞網鏇網願築壓(齋淵壓遞壓齋蓋構網積) = 4.35% for placebo, 2.86% for 5 mg-, 4.05% for 10 mg- and 4.29% for 20 mg-rupatadine-treated group 餘窪鏇淵遞淵範膚選願 (齋製鏇鑰願鑰構選鑰襯 ) 更多 | - | 2007-06-30 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用